Cancer Research Meeting Calendar EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, L.-T.
Right arrow Articles by Hung, W.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, L.-T.
Right arrow Articles by Hung, W.-C.
[Cancer Research 63, 3069-3072, June 15, 2003]
© 2003 American Association for Cancer Research

Advances in Brief

Histone Deacetylase Inhibitor Up-Regulates RECK to Inhibit MMP-2 Activation and Cancer Cell Invasion1

Li-Teh Liu, Hui-Chiu Chang, Lien-Chai Chiang and Wen-Chun Hung2

Graduate Institute of Medicine [L-T. L.], Departments of Physiology [H-C. C.] and Microbiology [L-C. C.], and School of Technology for Medical Sciences [W-C. H.], Kaohsiung Medical University, Kaohsiung 807, Taiwan

Histone deacetylase (HDAC) inhibitors are known to exert antimetastatic and antiangiogenic activity in vitro and in vivo. RECK is a membrane-anchored glycoprotein that negatively regulates matrix metalloproteinases (MMPs) and inhibits tumor metastasis and angiogenesis. In this study, we test the possibility that HDAC inhibitor may increase RECK expression to inhibit MMP activation and cancer cell invasion. Our results showed that trichostatin A (TSA) up-regulated RECK via transcriptional activation in CL-1 human lung cancer cells. Flow cytometric analysis demonstrated that RECK protein on cell surface was increased after treatment of TSA. Moreover, up-regulation of RECK expression by TSA attenuated MMP-2 activity. To explore whether HDAC inhibitor-induced inhibition of MMP-2 activation is indeed mediated via RECK, we used small interference RNA (siRNA) to block RECK expression and found that inhibition of RECK by siRNA abolished the inhibitory effect of TSA on MMP-2 activation. In addition, TSA suppressed the invasive ability of CL-1 cells. Taken together, this study reveals a novel mechanism by which HDAC inhibitors suppress tumor invasion and provides a new strategy for cancer therapy.




This article has been cited by other articles:


Home page
 Eur Heart JHome page
D. Pons, F. R. de Vries, P. J. van den Elsen, B. T. Heijmans, P. H.A. Quax, and J. W. Jukema
Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease
Eur. Heart J., February 1, 2009; 30(3): 266 - 277.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M.-R. Pan, M.-F. Hou, H.-C. Chang, and W.-C. Hung
Cyclooxygenase-2 Up-regulates CCR7 via EP2/EP4 Receptor Signaling Pathways to Enhance Lymphatic Invasion of Breast Cancer Cells
J. Biol. Chem., April 25, 2008; 283(17): 11155 - 11163.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. M. K. Pulukuri, B. Gorantla, and J. S. Rao
Inhibition of Histone Deacetylase Activity Promotes Invasion of Human Cancer Cells through Activation of Urokinase Plasminogen Activator
J. Biol. Chem., December 7, 2007; 282(49): 35594 - 35603.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. Huang, Z. Hu, M. Li, Y. Cui, Y. Li, L. Guo, W. Jiang, and S. H. Lu
ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity
Carcinogenesis, November 1, 2007; 28(11): 2274 - 2281.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M.-C. Hsu, H.-C. Chang, and W.-C. Hung
HER-2/neu transcriptionally activates Jab1 expression via the AKT/{beta}-catenin pathway in breast cancer cells
Endocr. Relat. Cancer, September 1, 2007; 14(3): 655 - 667.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Puri, A. Khramtsov, S. Ahmed, V. Nallasura, J. T. Hetzel, R. Jagadeeswaran, G. Karczmar, and R. Salgia
A Selective Small Molecule Inhibitor of c-Met, PHA665752, Inhibits Tumorigenicity and Angiogenesis in Mouse Lung Cancer Xenografts
Cancer Res., April 15, 2007; 67(8): 3529 - 3534.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
A. D.-A. Tran, T. P. Marmo, A. A. Salam, S. Che, E. Finkelstein, R. Kabarriti, H. S. Xenias, R. Mazitschek, C. Hubbert, Y. Kawaguchi, et al.
HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions
J. Cell Sci., April 15, 2007; 120(8): 1469 - 1479.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Uchida, T. Maruyama, M. Ono, K. Ohta, T. Kajitani, H. Masuda, T. Nagashima, T. Arase, H. Asada, and Y. Yoshimura
Histone Deacetylase Inhibitors Stimulate Cell Migration in Human Endometrial Adenocarcinoma Cells through Up-Regulation of Glycodelin
Endocrinology, February 1, 2007; 148(2): 896 - 902.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
L. Zeng, Q. Xiao, A. Margariti, Z. Zhang, A. Zampetaki, S. Patel, M. C. Capogrossi, Y. Hu, and Q. Xu
HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells
J. Cell Biol., September 25, 2006; 174(7): 1059 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-C. Chang, C.-Y. Cho, and W.-C. Hung
Silencing of the Metastasis Suppressor RECK by RAS Oncogene Is Mediated by DNA Methyltransferase 3b-Induced Promoter Methylation.
Cancer Res., September 1, 2006; 66(17): 8413 - 8420.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. W. Rinker-Schaeffer, J. P. O'Keefe, D. R. Welch, and D. Theodorescu
Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical Application.
Clin. Cancer Res., July 1, 2006; 12(13): 3882 - 3889.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. C. Newman, A. D. Bailey, and A. M. Weiner
Cockayne syndrome group B protein (CSB) plays a general role in chromatin maintenance and remodeling
PNAS, June 20, 2006; 103(25): 9613 - 9618.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M.-C. Hsu, H.-C. Chang, and W.-C. Hung
HER-2/neu Represses the Metastasis Suppressor RECK via ERK and Sp Transcription Factors to Promote Cell Invasion
J. Biol. Chem., February 24, 2006; 281(8): 4718 - 4725.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg
Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Simizu, S. Takagi, Y. Tamura, and H. Osada
RECK-Mediated Suppression of Tumor Cell Invasion Is Regulated by Glycosylation in Human Tumor Cell Lines
Cancer Res., August 15, 2005; 65(16): 7455 - 7461.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Michaelis, U. R. Michaelis, I. Fleming, T. Suhan, J. Cinatl, R. A. Blaheta, K. Hoffmann, R. Kotchetkov, R. Busse, H. Nau, et al.
Valproic Acid Inhibits Angiogenesis in Vitro and in Vivo
Mol. Pharmacol., March 1, 2004; 65(3): 520 - 527.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.